Accessibility Menu
Pelthos Therapeutics logo

Pelthos Therapeutics(NYSEMKT) PTHS

Market Cap$98.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-46%
5 YearN/A
1 Year+26%
1 Month-5%
$26.93
+4.28%
+1.11Today
Pelthos Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 25.822026-08-19
Pelthos Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.69%USD 28.912026-08-12
1 month-5.28%USD 27.262026-07-20
3 month-4.72%USD 27.102026-05-21
Year to date-16.71%USD 31.002025-12-31
1 year+25.89%USD 20.512025-08-19
Since inception-46.21%USD 48.002024-02-16

Pelthos Therapeutics Financials at a Glance

Market Cap

$98.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$43.30M

Net Income (TTM)

-$71.56M

EPS (TTM)

-$26.36

P/E Ratio

-0.98

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Price

$26.93

Volume

15,939.302

Open

$26.03

Previous Close

$25.82

Daily Range

$25.86 - $27.10

52-Week Range

$18.19 - $37.50

Estimated Earnings Date

Nov 12, 2026

PTHS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pelthos Therapeutics

Pelthos makes prescription skin treatments for children and adults. Its main products help treat common skin infections at home. The company focuses on conditions with few existing solutions.

Skin Deep: Pelthos’s Main Offerings

  • ZELSUVMI topical gel: Treats molluscum contagiosum, a viral skin infection, for adults and children (100% of 2025 revenue).
  • XEPI cream: Treats impetigo, a bacterial skin infection, for children and adults (acquired late 2025; no 2025 revenue).
  • XEGLYZE lotion: Treats head lice in children and adults (acquired late 2025; no 2025 revenue).
  • NITRICIL technology: Platform for delivering nitric oxide in topical medicines, supporting future product development.
  • NaV1.7 pain programs: Early-stage research for new pain relief treatments targeting sodium channels in nerves.

Growing Pains and Gains: Expansion Moves

  • Launched ZELSUVMI in July 2025 as the first at-home prescription for molluscum contagiosum.
  • Acquired U.S. rights to XEPI from Ferrer in November 2025.
  • Acquired global rights to XEGLYZE from Hatchtech Pty Ltd. in December 2025.
  • Secured $50 million venture loan in January 2026 to fund product launches.
  • Formed exclusive supply and license deals with Ligand Pharmaceuticals and Interquim for manufacturing and technology access.

What Makes Pelthos Stand Out

Pelthos controls its own manufacturing for key ingredients, reducing supply risks. Its products target skin conditions with few approved treatments, focusing on children and families. The company holds exclusive licenses and patents, supporting its position in niche dermatology markets.

Five Things You Need to Know

  • Revenue was $16.8 million in 2025, up from $0 in 2024.
  • Gross margin was about 75% in 2025, with $4.0 million cost of goods sold.
  • Operating loss was $32.4 million in 2025, up 326% from 2024.
  • Net loss was $43.3 million in 2025, up 441% from 2024.
  • Three wholesalers made up 89% of gross revenue in 2025.

Bottom Line

Pelthos has shifted from research to commercial sales, focusing on skin treatments for underserved conditions. The company’s growth relies on new product launches and careful management of costs and partnerships.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

92

CEO

Scott M. Plesha

Website

pelthos.com

Headquarters

Durham, NC 27703, US

PTHS Financials

Key Financial Metrics (TTM)

Gross Margin

54.72%

Operating Margin

-133.42%

Net Income Margin

-165.24%

Return on Equity

-218.94%

Return on Capital

-44.00%

Return on Assets

-52.10%

Earnings Yield

-1.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$98.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.83M

Volume

15.94K

Avg. Volume

49.31K

Financials (TTM)

Gross Profit

$23.70M

Operating Income

-$57.78M

EBITDA

-$63.05M

Operating Cash Flow

-$42.30M

Capital Expenditure

-$295.00K

Free Cash Flow

-$42.60M

Cash & ST Invst.

$24.56M

Total Debt

$73.11M

Pelthos Therapeutics Performance Analysis

Pelthos Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 16,795,000N/A
Pelthos Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-3126.8%
Q12026-03-3116.2%
Q22026-06-3043.1%
Pelthos Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.26313.0%
20232023-12-31USD -12.80200.2%
20242024-12-31USD -14.2711.5%
20252025-12-31USD -23.0461.4%
Pelthos Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-371.2%
Q42025-12-3172.9%
Q12026-03-3155.0%
Q22026-06-30-114.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$15.60M

N/A

Gross Profit

$10.67M

N/A

Gross Margin

68.40%

N/A

Market Cap

$98.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.07M

N/A

Employees

92

N/A

Net Income

-$23.42M

-579.0%

EBITDA

-$15.93M

-393.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$24.56M

+41406.1%

Total Debt

$73.11M

+3072.2%

Accounts Receivable

$14.48M

+35746.5%

Inventory

$21.47M

N/A

Long Term Debt

$72.46M

N/A

Short Term Debt

$645.00K

-72.0%

Return on Assets

-52.10%

N/A

Return on Invested Capital

-54.82%

N/A

Free Cash Flow

-$7.67M

-1614.4%

Operating Cash Flow

-$7.66M

-1614.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LIXTLixte Biotechnology Holdings, Inc.
$7.21-6.00%
CINGCingulate Inc.
$5.13-2.66%
ENLVEnlivex Therapeutics Ltd.
$1.52-12.14%
PASGPassage Bio, Inc.
$4.54+0.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.83+0.06%
IBITiShares Bitcoin Trust
$41.19+0.06%
SPCXSpace Exploration Technologies
$130.74-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.82-0.04%

Questions About PTHS

What is the current price of Pelthos Therapeutics?

Pelthos Therapeutics is trading at $26.93 per share.

What is the 52-week range for Pelthos Therapeutics?

Over the past 52 weeks, Pelthos Therapeutics has traded between $18.19 and $37.50.

How much debt does Pelthos Therapeutics have?

As of the most recent reporting period, Pelthos Therapeutics reported total debt of $73.11M.

How much cash does Pelthos Therapeutics have on hand?

Pelthos Therapeutics reported $24.56M in cash and cash equivalents in its most recent financial results.

What is Pelthos Therapeutics’s dividend yield?

Pelthos Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services